We are live on ! Find out more
AIDX icon

20/20 Biolabs

16 hedge funds and large institutions have $236K invested in 20/20 Biolabs in 2026 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

7% more funds holding

Funds holding: 15 → 16 (+1)

0.18% less ownership

Funds ownership: 4.41% → 4.24% (-0.18%)

0% less capital inflows, than outflows

Capital inflows: $43.8K | Capital outflows: $44K

Holders
16
Holders Change
+1
Holders Change %
+6.67%
% of All Funds
0.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
5
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

AIDX Hedge Fund Activity: Q3 2026 in Review

16 of the 8,207 institutional investors tracked by Wall St. Rank reported a position in 20/20 Biolabs (AIDX) for Q3 2026, worth a combined $236K — down 21% from $297K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new AIDX positions and 2 closed out — a net gain of 1 holder — while 5 added to existing stakes and 1 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $21K. The largest seller was HRT Financial, cutting an estimated $38.4K.

  • 16 institutional investors held 20/20 Biolabs (AIDX) as of Q3 2026, up from 15 in Q2 2026.
  • Funds reported $236K of 20/20 Biolabs stock for Q3 2026, down 21% quarter-over-quarter.
  • 3 funds opened new 20/20 Biolabs positions in Q3 2026 and 2 closed out, a net change of +1 holder.
  • The largest 20/20 Biolabs buyer in Q3 2026 was Citadel Advisors, an estimated $21K added.
  • The largest 20/20 Biolabs seller in Q3 2026 was HRT Financial, an estimated $38.4K sold.

Based on aggregated 13F filings for Q3 2026.